TRAF3 and B-cell neoplasm: Our findings suggest that oridonin or closely related NF-κB2 inhibitors should be considered as new candidates for the treatment of B cell neoplasms characterized by genetic/epigenetic inactivation of TRAF3 or TRAF3-dependent signaling pathways.